Followers | 247 |
Posts | 49957 |
Boards Moderated | 51 |
Alias Born | 08/29/2007 |
Monday, July 03, 2023 2:41:56 PM
Gene-Editing Therapies Could Rearrange Healthcare Expenditures In The US
ARK Invest_Illustration_Ali Urman_Final_Circle 400 px By Ali Urman | @aurmanARK
Analyst
Last week, Vertex Pharmaceuticals presented3 promising results from a Phase I/II trial focused on Type 1 Diabetes (T1D): VX-880, an allogeneic stem-cell derived islet cell therapy infused into the hepatic portal vein for T1D patients with severe hypoglycemia. Importantly, the six patients produced endogenous insulin, reducing the need for exogenous insulin and showing blood glucose control with a reduction of HbA1c.
In the US today, healthcare spending approximates $4.3 trillion,4 of which therapeutics accounts for ~15%, or $600 billion,5 as shown below.
In our view, novel gene-editing therapies could command premium pricing by shifting healthcare expenditures from chronic disease management to one-dose therapies like VX-880. Addressing diabetes, for example, therapeutics account for 30% of total direct and indirect costs, as shown below. If emerging drugs like VX-880 were to shift costs from chronic disease management to one-dose therapies, curative therapeutics could take share from chronic treatments.
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent VRTX News
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 05/10/2024 12:01:31 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 05/08/2024 12:54:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:14:28 PM
- Disney Slashes Streaming Losses, UBS shoots up 9% as profit triples expectations, and More in Earnings • IH Market News • 05/07/2024 11:46:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:03:09 PM
- Vertex Reports First Quarter 2024 Financial Results • Business Wire • 05/06/2024 08:01:00 PM
- Index Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices Rise • IH Market News • 05/06/2024 12:09:15 PM
- Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older • Business Wire • 04/26/2024 03:43:00 PM
- VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES • PR Newswire (Canada) • 04/23/2024 04:45:00 AM
- VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES • PR Newswire (US) • 04/23/2024 04:45:00 AM
- VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES • PR Newswire (US) • 04/23/2024 04:45:00 AM
- Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain • Business Wire • 04/18/2024 12:00:00 PM
- Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News • IH Market News • 04/11/2024 11:24:54 AM
- Vertex Enters Into Agreement to Acquire Alpine Immune Sciences • Business Wire • 04/10/2024 08:01:00 PM
- Vertex Enters Into Agreement to Acquire Alpine Immune Sciences • Business Wire • 04/10/2024 08:01:00 PM
- Vertex to Announce First Quarter 2024 Financial Results on May 6 • Business Wire • 04/09/2024 08:05:00 PM
- Vertex annonce que la présentation de drogue nouvelle d'Exagamglogène Autotemcel (exa-cel) a été acceptée pour évaluation prioritaire par Santé Canada pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusion • PR Newswire (Canada) • 04/01/2024 03:00:00 PM
- Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia • PR Newswire (Canada) • 04/01/2024 03:00:00 PM
- Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease • Business Wire • 04/01/2024 12:00:00 PM
- Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • Business Wire • 03/21/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:08:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:02:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 09:59:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 09:55:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 09:50:38 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM